Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
Clinical Infectious Diseases · 18.07.2025 · 80 (6) · 1235-1244
DOI: 10.1093/cid/ciaf029 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 17.02.2025. Verfasst von Anne F Luetkemeyer und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, University of California San Francisco, San Francisco, Ca…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases of the National Institutes of Health, NIAID NIH HHS, Shionogi & Co., Ltd..
Abstract (Originalsprache)
Background
Ensitrelvir, a severe acute respiratory syndrome coronavirus-2 main protease inhibitor, has demonstrated clinical and virologic efficacy in previous studies.
Methods
In this global phase 3 trial, nonhospitalized adults with mild-to-moderate coronavirus disease 2019 (COVID-19) and symptom onset within 5 days were randomized (1:1) to receive once-daily ensitrelvir (375 mg day 1, 125 mg days 2–5) or blinded matching placebo. The primary endpoint was the restricted mean time to sustained (≥2 days) resolution of 15 COVID-19 symptoms, recorded in participant daily diaries, through day 29 in participants starting treatment within 3 days after symptom onset. Virologic efficacy and safety were assessed.
Results
Of 2093 participants, 1888 started treatment within 3 days after symptom onset. Mean time to symptom resolution was 12.5 and 13.1 days with ensitrelvir and placebo, respectively (difference, −0.6 days; 95% confidence interval, −1.38 to 0.19; P = .14). On day 4, ensitrelvir reduced least-squares mean RNA by 0.72 log10 copies/mL more than placebo (95% confidence interval, 0.55–0.90). Among those with positive viral cultures at enrollment, 274/287 (95.5%) ensitrelvir-treated versus 210/280 (75.0%) placebo-treated participants had negative cultures on day 4. RNA rebound was similar (<1.5%) between groups. The proportion of participants with ≥1 adverse event was similar with ensitrelvir (61.5%) and placebo (60.6%). No treatment-related serious adverse events or deaths occurred. Three (0.3%) ensitrelvir-treated and 1 (0.1%) placebo-treated participants had COVID-19–related hospitalizations by day 29.
Conclusions
Despite the evidence of antiviral activity with ensitrelvir, this trial did not demonstrate a significant difference in time to sustained symptom resolution. Clinical Trials Registration Number NCT05305547.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, University of California San Francisco, San Francisco, California, USA.
- Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
- Biostatistics, Shionogi B.V., London, United Kingdom.
- Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Division of HIV Medicine, Lundquist Institute at Harbor University of California Los Angeles, Torrance, California, USA.
- Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Anne F Luetkemeyer, Kara W Chew, Linda J Harrison, Eric S Daar, Courtney V Fletcher, Alexander L Greninger, Jonathan Z Li, David Wohl, Methee Chayakulkeeree, Simon Portsmouth, Takeki Uehara, Davey Smith, Judith S Currier
Förderung
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health
- NIAID NIH HHS
- Shionogi & Co., Ltd.
Zitieren
APA
Luetkemeyer, A. F., Chew, K. W., Lacey, S., Hughes, M. D., Harrison, L. J., Daar, E. S., Eron, J., Fletcher, C. V., Greninger, A. L., Hessinger, D., Li, J. Z., Mailhot, D., Wohl, D., Chayakulkeeree, M., Mendoza, J. L. A., Elistratova, P., Makinde, O., Morgan, G., Portsmouth, S., …, & Currier, J. S. (2025). Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 80(6), 1235-1244. https://doi.org/10.1093/cid/ciaf029
Vancouver
Luetkemeyer AF, Chew KW, Lacey S, Hughes MD, Harrison LJ, Daar ES, et al. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. Clinical Infectious Diseases. 2025;80(6):1235-1244. doi:10.1093/cid/ciaf029
BibTeX
@article{Luetkemeyer2025,
author = {Luetkemeyer, Anne F and Chew, Kara W and Lacey, Stuart and Hughes, Michael D and Harrison, Linda J and Daar, Eric S and Eron, Joseph and Fletcher, Courtney V and Greninger, Alexander L and Hessinger, Diane and Li, Jonathan Z and Mailhot, David and Wohl, David and Chayakulkeeree, Methee and Mendoza, Jose Luis Accini and Elistratova, Polina and Makinde, Oluwaseun and Morgan, Gareth and Portsmouth, Simon and Uehara, Takeki and Smith, Davey and Currier, Judith S},
title = {Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {6},
pages = {1235--1244},
doi = {10.1093/cid/ciaf029}
}
EUVIMED